Frankfurt - Delayed Quote EUR

PolyPeptide Group AG (8H0.F)

21.55
+0.35
+(1.65%)
As of 9:15:02 AM GMT+2. Market Open.
Loading Chart for 8H0.F
  • Previous Close 21.20
  • Open 21.55
  • Bid 21.35 x --
  • Ask 21.60 x --
  • Day's Range 21.55 - 21.55
  • 52 Week Range 20.05 - 21.55
  • Volume 1
  • Avg. Volume 0
  • Market Cap (intraday) 723.877M
  • Beta (5Y Monthly) 1.08
  • PE Ratio (TTM) --
  • EPS (TTM) -0.59
  • Earnings Date Aug 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

www.polypeptide.com

1,362

Full Time Employees

--

Fiscal Year Ends

Recent News: 8H0.F

View More

Performance Overview: 8H0.F

Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

8H0.F
7.48%
MSCI WORLD (^990100-USD-STRD)
2.12%

1-Year Return

8H0.F
7.48%
MSCI WORLD (^990100-USD-STRD)
0.00%

3-Year Return

8H0.F
7.48%
MSCI WORLD (^990100-USD-STRD)
43.87%

5-Year Return

8H0.F
7.48%
MSCI WORLD (^990100-USD-STRD)
86.71%

Compare To: 8H0.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 8H0.F

View More

Valuation Measures

Annual
As of 5/12/2025
  • Market Cap

    710.01M

  • Enterprise Value

    735.85M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.07

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.17

  • Enterprise Value/EBITDA

    25.89

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.81%

  • Return on Assets (ttm)

    -0.51%

  • Return on Equity (ttm)

    -5.30%

  • Revenue (ttm)

    336.79M

  • Net Income Avi to Common (ttm)

    -19.56M

  • Diluted EPS (ttm)

    -0.59

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    68.28M

  • Total Debt/Equity (mrq)

    29.36%

  • Levered Free Cash Flow (ttm)

    -67.96M

Research Analysis: 8H0.F

View More

Company Insights: 8H0.F

Research Reports: 8H0.F

View More